CONMED Corporation (FRA:EC8)
Germany · Delayed Price · Currency is EUR | Market Cap | 875.29M -47.0% |
| Revenue (ttm) | 1.19B +4.1% |
| Net Income | 47.57M -53.8% |
| EPS | 1.54 -53.6% |
| Shares Out | n/a |
| PE Ratio | 18.40 |
| Forward PE | 7.46 |
| Dividend | 0.34 (1.18%) |
| Ex-Dividend Date | Sep 15, 2025 |
| Volume | n/a |
| Open | 28.80 |
| Previous Close | 29.00 |
| Day's Range | 28.60 - 28.80 |
| 52-Week Range | 28.60 - 52.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 29, 2026 |
About CONMED
CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as supporting products include powered resection instruments , fluid management, and visualization systems an... [Read more]
Financial Performance
In 2025, CONMED's revenue was $1.37 billion, an increase of 5.18% compared to the previous year's $1.31 billion. Earnings were $47.06 million, a decrease of -64.47%.
Financial numbers in USD Financial StatementsNews
Conmed appoints Martin, Mirviss to its Board of Directors
Conmed (CNMD) announced the appointment of Celine Martin and Jeff Mirviss to its Board of Directors, effective July 1, 2026. Martin will serve as a member of the Audit Committee…
CONMED Corporation Appoints Celine Martin and Jeff Mirviss to its Board of Directors
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced the appointment of Celine Martin and Jeff Mirviss to its Board of Directors (“Board”), effective July 1, 2026. Ms. Martin ...
CONMED Transcript: AGM 2026
The meeting confirmed proper notice and quorum, recognized a retiring Board member, and presented three proposals: Director elections, executive compensation, and auditor ratification. All proposals passed by majority vote, with final results to be filed on Form 8-K.
Conmed price target lowered to $40 from $52 at BofA
BofA lowered the firm’s price target on Conmed (CNMD) to $40 from $52 and keeps a Neutral rating on the shares. After having hosted 34 medtech companies last week in…
Conmed price target lowered to $40 from $43 at JPMorgan
JPMorgan lowered the firm’s price target on Conmed (CNMD) to $40 from $43 and keeps a Neutral rating on the shares.
Conmed reports Q1 EPS 89c, consensus 82c
Reports Q1 revenue $317.0M, consensus $310.6M. “Our 2025 momentum continued in the first quarter as we delivered revenue and adjusted earnings ahead of our expectations,” said Patrick J. Beyer, CONMED...
Conmed backs FY26 EPS view of $4.30-$4.45, consensus $4.45
Narrows FY26 revenue view to $1.35B-$1.375B from $1.345B-$1.375B, consensus $1.36B.
CONMED Earnings Call Transcript: Q1 2026
Q1 2026 saw organic sales growth and margin improvement, driven by orthopedics and key platforms, despite a GI product line exit and higher interest expense. Full-year guidance was raised for organic growth, with EPS guidance maintained.
CONMED Earnings release: Q1 2026
CONMED released its Q1 2026 earnings on April 29, 2026, summarizing the period's financial results.
CONMED Slides: Q1 2026
CONMED has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 29, 2026.
CONMED Quarterly report: Q1 2026
CONMED has published its Q1 2026 quarterly earnings report on April 29, 2026.
CONMED Corporation Announces First Quarter 2026 Financial Results
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced financial results for the first quarter ended March 31, 2026. First Quarter 2026 Highlights Sales of $317.0 million decrea...
CONMED Proxy statement: Proxy filing
CONMED filed a proxy statement on April 7, 2026, providing details for shareholder voting and corporate governance matters.
CONMED Proxy statement: Proxy filing
CONMED filed a proxy statement on April 7, 2026, providing details for shareholder voting and corporate governance matters.
CONMED Corporation to Announce First Quarter 2026 Financial Results on April 29, 2026
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the first quarter 2026 after the market close on Wednesday, April 29, 2026. The ...
Conmed assumed with an Equal Weight at Wells Fargo
Wells Fargo initiated coverage of assumed with an Equal Weight rating and $42 price target The firm is maintaining the current rating, price target and estimates.
Conmed downgraded to Neutral from Overweight at Piper Sandler
Piper Sandler analyst Matt O’Brien downgraded Conmed (CNMD) to Neutral from Overweight with a price target of $39, down from $55. The company’s AirSeal “did not completely implode” after Intuitive…
CONMED Earnings Call Transcript: Q4 2025
Fourth quarter sales grew 7.9% year-over-year, led by strong orthopedic and international performance, while adjusted EPS rose 6.7%. The company exited its GI product lines to focus on high-growth platforms, improved supply chain, and authorized a $150M share repurchase.
CONMED Annual report: Q4 2025
CONMED has published its Q4 2025 annual report on January 28, 2026.
CONMED Annual report: Q4 2025
CONMED has published its Q4 2025 annual report on January 28, 2026.
CONMED Earnings release: Q4 2025
CONMED released its Q4 2025 earnings on January 28, 2026, summarizing the period's financial results.
CONMED Slides: Q4 2025
CONMED has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on January 28, 2026.
Conmed reports Q4 adjusted EPS $1.43, consensus $1.32
Reports Q4 revenue $373.2M, consensus $366.88M. “Our fourth quarter results reflect steady execution across the business as well as progress on our operational initiatives,” said Patrick J. Beyer, CON...
Conmed sees FY26 adjusted EPS $4.30-$4.45, consensus $4.42
Sees FY26 revenue $1.345B-$1.375B, consensus $1.37B.
CONMED Corporation Announces Fourth Quarter and Full-Year 2025 Financial Results
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced financial results for the fourth quarter and full-year ended December 31, 2025. Fourth Quarter 2025 Highlights Sales of $3...